Vaxcyte Files Preliminary Prospectus for Convertible Senior Notes Offering
PCVX sits 82% above its 52-week low of $39.87 on elevated volume (11× avg).
Summary
Vaxcyte filed the preliminary prospectus supplement for its convertible senior notes offering, part of a $1.15B concurrent capital raise announced after positive Phase 3 data for VAX-31. The notes mature in 2032 and are convertible at a premium to the $73.82 reference price.
Key Events · Financing and Capital Events · PCVX
-
Convertible Notes Offering Formalized
Vaxcyte filed the preliminary prospectus supplement for its convertible senior notes due 2032, part of the $1.15B concurrent offerings announced October 5, 2026. The notes are senior unsecured obligations with an initial conversion price of approximately $73.82 per share, representing a premium to the last reported sale price.
-
Concurrent Equity Offering Structure
The notes offering is being conducted concurrently with a separate equity offering of common stock and pre-funded warrants. Completion of either offering is not contingent on the other, and the company may receive proceeds from one without the other.
-
Cash Position Disclosed
The filing discloses preliminary unaudited cash, cash equivalents and investments of approximately $2.3 billion as of September 30, 2026, providing a strong liquidity baseline ahead of the VAX-31 commercial launch.
-
Use of Proceeds
Net proceeds will fund VAX-31 adult and pediatric clinical development, manufacturing scale-up and inventory build for potential commercial launch, medical affairs and commercial investments, and general corporate purposes.
Analysis · PCVX · Life Sciences
Vaxcyte is formalizing the convertible notes component of its $1.15B concurrent capital raise, announced just yesterday on the heels of positive Phase 3 OPUS-1 data for VAX-31. The notes mature in 2032 and are convertible into common stock at a premium to the $73.82 reference price, with settlement at the company's election in cash, shares, or a combination. The company also disclosed approximately $2.3 billion in cash as of September 30, 2026, providing a strong liquidity baseline. The offering is not contingent on the concurrent equity offering, and vice versa. This is a substantial capital raise that will fund the VAX-31 commercial launch and manufacturing scale-up, but it introduces potential future dilution to existing shareholders upon conversion.
How filings like this one have moved
In the 30 days to Oct 6, 2026, 36.5% of the 1012 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCVX was trading at $72.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11B. The 52-week trading range was $39.87 to $90.75. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.